// App-Quantinova.ai

1534 : Long-term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study

Researchers

Presenter

  • Philip Mease

Principal Investigators

  • Dafna Gladman

  • Filip Van den Bosch

  • Anna Rychlewska-Hanczewska

  • Chantal Tasset

  • Luc Meuleners

  • Mona Trivedi

  • Jingjing Gao

  • Robin Besuyen

  • Philip Helliwell

Medical Centers

  • University of Oxford, Oxford, United Kingdom

  • Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA

  • Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada

  • Ghent University Hospital, Ghent, Belgium

  • 5ai centrum medyczne sp. z o.o. sp.k., Poznan, Poland, Poznan, Poland

  • Galapagos, Mechelen, Belgium

  • Gilead Sciences Inc, Foster City, United States of America, Foster City, CA

  • University of Leeds, Leeds, United Kingdom

Locations

  • United Kingdom

  • United States

  • Canada

  • Belgium

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Filgotinib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved